Part of NATIONAL HEALTH SERVICE
Clinical Trials
1
1 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1834
No trial phase data available
Active, not recruiting
1
100.0%
No approval data available
- Autolus Therapeutics has dosed the first patient in its Phase 1 BOBCAT trial evaluating obecabtagene autoleucel (obe-cel) for progressive multiple sclerosis, marking a significant milestone in CAR-T therapy expansion beyond oncology. - The trial will enroll up to 18 adult patients with refractory progressive MS to assess safety, tolerability, and preliminary efficacy of the CD19-directed CAR-T therapy. - Obe-cel features a unique fast target binding off-rate mechanism designed to minimize excessive T cell activation and has been studied in over 400 patients with a well-characterized safety profile. - Progressive MS affects approximately 300,000 individuals in the US, with more than half experiencing disability progression despite current disease-modifying treatments, representing a significant unmet medical need.
- AstraZeneca's CARES Phase III clinical programme evaluating anselamimab in patients with Mayo stages IIIa and IIIb light chain amyloidosis did not achieve statistical significance for the primary endpoint of time to all-cause mortality and cardiovascular hospitalizations. - Despite missing the primary endpoint in the overall population, anselamimab demonstrated highly clinically meaningful improvement in survival and cardiovascular hospitalization rates in a prespecified patient subgroup compared to placebo. - The investigational anti-fibril monoclonal antibody represents a potentially first-in-class approach to clearing amyloid deposits in AL amyloidosis, a rare and life-threatening disorder affecting an estimated 74,000 patients worldwide. - Anselamimab was well tolerated with balanced adverse events between treatment and placebo arms, and Alexion plans to share full results with global health authorities and present data at upcoming medical meetings.
- Katie Tinkler, a lupus patient, receives CAR T-cell therapy in a UK clinical trial, marking a potential breakthrough in lupus treatment. - The therapy genetically modifies cells to target and attack cells driving lupus inflammation, offering a possible cure. - Tinkler expresses hope that the trial's success could extend to other autoimmune diseases, providing an endpoint for patients. - The treatment, administered at University College London Hospitals, aims to provide a lupus-free life, a significant advancement over current immunosuppressive treatments.
- Three patients in the UK receive CAR T-cell therapy on the NHS in a trial offering potential remission for severe lupus, a disease affecting 70,000 in the UK. - The therapy genetically modifies immune cells to target and attack cells driving lupus inflammation, providing a possible cure where only immunosuppression was available. - Katie Tinkler, a lupus patient for 30 years, expresses hope that the trial's results will offer an endpoint for those with autoimmune diseases, improving their quality of life. - University College London Hospitals NHS Foundation Trust (UCLH) is conducting the trial, marking a significant step forward in treating autoimmune conditions like lupus.
- A clinical trial using targeted radioactive therapy, ATT001, has shown early success in shrinking aggressive glioblastoma tumors by half in a patient. - The CITADEL-123 trial involves implanting a device to deliver ATT001 directly into the tumor, causing lethal damage to cancer cells while sparing healthy tissue. - The experimental treatment, developed by UCLH, offers a potential lifeline for patients with recurrent glioblastoma, who typically have a survival prognosis of less than a year. - Researchers plan to increase the radiation dose and combine ATT001 with immunotherapy to further enhance the treatment's effectiveness against brain tumors.
